Advanced thymic cancer treated with carboplatin and paclitaxel in a patient undergoing hemodialysis.
Advanced thymic cancer treated with carboplatin and paclitaxel in a patient undergoing hemodialysis.
复制标题
DOI：
10.2169/internalmedicine.54.3484
复制
发表时间：
2015
影响因子：
1.2
通讯作者：
S. Miura;H. Kagamu;Takehito Sakai;K. Nozaki;Katsuaki Asakawa;H. Moro;M. Okajima;Satoshi Watanabe;Suguru Yamamoto;N. Iino;S. Goto;J. Kazama;H. Yoshizawa;I. Narita
中科院分区：
文献类型：
--
作者：
S. Miura;H. Kagamu;Takehito Sakai;K. Nozaki;Katsuaki Asakawa;H. Moro;M. Okajima;Satoshi Watanabe;Suguru Yamamoto;N. Iino;S. Goto;J. Kazama;H. Yoshizawa;I. Narita
一位53岁男性无症状前纵隔肿瘤接受血液透析被转介到我们的机构。根据胸部断层扫描引导下的活检结果，他被诊断为胸腺基底细胞癌，并成功地在第一天用卡铂（300 mg/m(2)/天）和紫杉醇（200 mg/m(2)/天）治疗，为期6个3周的周期。据我们所知，这是第一篇关于血液透析患者中基于紫杉醇体表面积的卡铂剂量定义方法有效性的报道。因此，该报告可能对治疗卡铂和紫杉醇治疗的血液透析患者有用。
A 53-year-old man with an asymptomatic anterior mediastinal tumor undergoing hemodialysis was referred to our institution. He was diagnosed with thymic basaloid carcinoma based on the findings of a chest tomography-guided biopsy and successfully treated with carboplatin (300 mg/m(2)/day) and paclitaxel (200 mg/m(2)/day) on day 1 for six three-week cycles. To our knowledge, this is the first report regarding the efficiency of a carboplatin dose-definition method based on the body surface area with paclitaxel in a hemodialysis patient. This report may therefore be useful for treating hemodialysis patients who are candidates for carboplatin and paclitaxel therapy.